NovImmune raised €41M in a Series C round in May 2009. The company is based in Plan-les-Ouates, Switzerland. Investors in the round: Aravis Ventures, BZ Bank, LODH Immunology Fund and 3 others. Data as of 6 Aug 2026.
No source on record — unverified.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
